{"id":35921,"date":"2025-06-24T23:18:21","date_gmt":"2025-06-24T15:18:21","guid":{"rendered":"https:\/\/flcube.com\/?p=35921"},"modified":"2025-06-24T23:18:22","modified_gmt":"2025-06-24T15:18:22","slug":"vcanbio-submits-clinical-trial-application-for-vum02-in-severe-pneumonia-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35921","title":{"rendered":"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China-based Vcanbio Cell &amp; Gene Engineering Corp., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/600645:SHA\">SHA: 600645<\/a>) announced that its clinical trial application for VUM02, a therapeutic biologic product derived from human umbilical cord mesenchymal stem cells, has been accepted for review by the Center for Drug Evaluation (CDE). The product is being developed for the treatment of severe and critical pneumonia.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Product Profile<\/strong><br>VUM02 is an internally developed cryopreserved stem-cell preparation. It is derived from umbilical cord tissue of healthy fetuses and undergoes isolation, screening, and in vitro amplification. Currently, no similar product has been approved for this indication globally, with VUM02 being the most advanced in clinical development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/600645_20250624_MU1O.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600645_20250624_MU1O.\"><\/object><a id=\"wp-block-file--media-d89ce031-0640-4cc0-8dd0-395fc97779f7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/600645_20250624_MU1O.pdf\">600645_20250624_MU1O<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/600645_20250624_MU1O.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d89ce031-0640-4cc0-8dd0-395fc97779f7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Vcanbio Cell &amp; Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35923,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,1039,243],"class_list":["post-35921","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-sha-600645","tag-vcanbio-cell-gene-engineering"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Vcanbio Cell &amp; Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial application for VUM02, a therapeutic biologic product derived from human umbilical cord mesenchymal stem cells, has been accepted for review by the Center for Drug Evaluation (CDE). The product is being developed for the treatment of severe and critical pneumonia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35921\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment\" \/>\n<meta property=\"og:description\" content=\"China-based Vcanbio Cell &amp; Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial application for VUM02, a therapeutic biologic product derived from human umbilical cord mesenchymal stem cells, has been accepted for review by the Center for Drug Evaluation (CDE). The product is being developed for the treatment of severe and critical pneumonia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35921\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-24T15:18:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T15:18:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2406.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35921#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35921\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment\",\"datePublished\":\"2025-06-24T15:18:21+00:00\",\"dateModified\":\"2025-06-24T15:18:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35921\"},\"wordCount\":120,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35921#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2406.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"SHA: 600645\",\"Vcanbio Cell &amp; Gene Engineering\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35921#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35921\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35921\",\"name\":\"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35921#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35921#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2406.webp\",\"datePublished\":\"2025-06-24T15:18:21+00:00\",\"dateModified\":\"2025-06-24T15:18:22+00:00\",\"description\":\"China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial application for VUM02, a therapeutic biologic product derived from human umbilical cord mesenchymal stem cells, has been accepted for review by the Center for Drug Evaluation (CDE). The product is being developed for the treatment of severe and critical pneumonia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35921#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35921\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35921#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2406.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2406.webp\",\"width\":1080,\"height\":608,\"caption\":\"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35921#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial application for VUM02, a therapeutic biologic product derived from human umbilical cord mesenchymal stem cells, has been accepted for review by the Center for Drug Evaluation (CDE). The product is being developed for the treatment of severe and critical pneumonia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35921","og_locale":"en_US","og_type":"article","og_title":"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment","og_description":"China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial application for VUM02, a therapeutic biologic product derived from human umbilical cord mesenchymal stem cells, has been accepted for review by the Center for Drug Evaluation (CDE). The product is being developed for the treatment of severe and critical pneumonia.","og_url":"https:\/\/flcube.com\/?p=35921","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-24T15:18:21+00:00","article_modified_time":"2025-06-24T15:18:22+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2406.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35921#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35921"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment","datePublished":"2025-06-24T15:18:21+00:00","dateModified":"2025-06-24T15:18:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35921"},"wordCount":120,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35921#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2406.webp","keywords":["Clinical trial approval \/ initiation","SHA: 600645","Vcanbio Cell &amp; Gene Engineering"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35921#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35921","url":"https:\/\/flcube.com\/?p=35921","name":"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35921#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35921#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2406.webp","datePublished":"2025-06-24T15:18:21+00:00","dateModified":"2025-06-24T15:18:22+00:00","description":"China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial application for VUM02, a therapeutic biologic product derived from human umbilical cord mesenchymal stem cells, has been accepted for review by the Center for Drug Evaluation (CDE). The product is being developed for the treatment of severe and critical pneumonia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35921#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35921"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35921#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2406.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2406.webp","width":1080,"height":608,"caption":"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35921#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2406.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35921"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35921\/revisions"}],"predecessor-version":[{"id":35924,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35921\/revisions\/35924"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35923"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}